亿帆医药(002019.SZ)：2025年中报净利润为3.04亿元、较去年同期上涨19.91%

Core Insights - The company reported a total revenue of 2.635 billion yuan for the first half of 2025, marking a slight increase of 3.02 million yuan or 0.11% year-on-year, achieving three consecutive years of growth [1] - The net profit attributable to shareholders reached 304 million yuan, an increase of 50.42 million yuan or 19.91% year-on-year, achieving two consecutive years of growth [1] - The net cash inflow from operating activities was 286 million yuan, up by 142 million yuan or 98.99% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio stands at 31.70% [3] - The gross profit margin is 48.57%, an increase of 2.19 percentage points from the previous quarter and 0.81 percentage points from the same period last year [3] - The return on equity (ROE) is 3.46%, up by 0.49 percentage points year-on-year [3] Earnings Per Share - The diluted earnings per share (EPS) is 0.25 yuan, an increase of 0.04 yuan or 19.05% year-on-year, achieving two consecutive years of growth [3] Asset Management - The total asset turnover ratio is 0.21 times [3] - The inventory turnover ratio is 1.20 times [3] Shareholder Structure - The number of shareholders is 41,100, with the top ten shareholders holding 601 million shares, accounting for 49.38% of the total share capital [3] - The largest shareholder, Cheng Xianfeng, holds 40.82% of the shares [3]